Login to Your Account



Poxel's Imeglimin Hits Phase II Endpoints in Type II Diabetes

By Cormac Sheridan
Staff Writer

Thursday, November 8, 2012

Poxel SA's lead oral diabetes drug, imeglimin, reached the primary endpoint in a Phase II trial in Type II diabetes patients, demonstrating statistically significant decreases in plasma glucose and fasting plasma glucose levels when administered in combination with sitagliptin vs. treatment with sitagliptin alone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription